Mega Lifesciences PCL (BKK:MEGA)

Market Cap	26.37B
Revenue (ttm)	15.39B
Net Income (ttm)	2.01B
Shares Out	871.87M
EPS (ttm)	2.31
PE Ratio	13.11
Forward PE	11.00
Dividend	1.60 (5.29%)
Ex-Dividend Date	Mar 7, 2025

Volume	353,243
Average Volume	696,384
Open	30.25
Previous Close	30.25
Day's Range	29.50 - 30.25
52-Week Range	28.75 - 43.25
Beta	0.44
RSI	39.36
Earnings Date	May 9, 2025

About Mega Lifesciences PCL

Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures and sells health food supplements, prescription pharmaceutical products, over-the-counter products, herbal products, vitamins, and fast-moving consumer goods in Southeast Asia and Sub-Saharan Africa. The company operates in three segments: Brands, Distribution, and Original Equipment Manufacture (OEM). It provides various medicines for allergies; blood circulation and memory; bone and joint; liver and digestive; diabetics; eyes, heart, and skin care; pain, sl...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1982
• Employees: 900
• Stock Exchange: Stock Exchange of Thailand
• Ticker Symbol: MEGA

Financial Performance

In 2024, Mega Lifesciences PCL's revenue was 15.39 billion, a decrease of -2.10% compared to the previous year's 15.72 billion. Earnings were 2.01 billion, an increase of 0.99%.